Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer

Expert Opin Emerg Drugs. 2022 Sep;27(3):289-300. doi: 10.1080/14728214.2022.2113377. Epub 2022 Oct 6.

Abstract

Introduction: Over the last decade, immune checkpoint inhibitors (ICIs) have impacted on the standard therapy for patients with non-small cell lung cancer (NSCLC). ICIs first showed efficacy in patients with advanced disease who had progressed after chemotherapy, later reaching the first-line therapy context alone, in combination with chemotherapy, and/or with dual-immunotherapy regimens.

Areas covered: Most of their benefit is, however, restricted to just 20% of patients due to primary or emergence of acquired resistance. In this review, we will describe the role of new emerging ICIs in the current panorama of NSCLC therapeutic approaches, not only in metastatic disease but also in locally advanced stage disease, with specific focus on those drugs under investigation in Phase 2/3 clinical trials.

Expert opinion: Several new ICIs are now under investigation to optimize NSCLC patient management; these are usually used in combination with other well-known agents, such as 'traditional' ICIs and chemotherapy, or with other newly developed drugs. Identification of better biomarkers will provide personalized treatment approaches to overcome patient-specific immune resistance.

Keywords: Emerging drugs; immune checkpoint inhibitor; non-small cell lung cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immunotherapy
  • Lung Neoplasms* / drug therapy

Substances

  • Immune Checkpoint Inhibitors